New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

Dexcom announced today that its G6 continuous glucose monitor (CGM) is being worn by astronauts as part of the Polaris Dawn ...

DexCom (NASDAQ: DXCM) is a big name in diabetes care. Its continuous glucose monitors (CGMs) help people track their blood glucose levels. But the stock has been performing poorly this year amid ...

Investors have been bearish on DexCom's numbers all this past year. The opportunity in diabetes care, however, remains significant in the long run. The launch of glucose monitor Stelo should ...

New York, New York--(Newsfile Corp. - September 14, 2024) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM ...

SAN DIEGO, September 18, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third ...

Patients could buy a pack of two sensors at a one-time price of $99 or opt for a subscription to get a monthly delivery for $89, Dexcom said. In June, rival Abbott Laboratories received the ...

Patients could buy a pack of two sensors at a one-time price of $99 or opt for a subscription to get a monthly delivery for $89, Dexcom said. Abbott had said it plans to launch Lingo in the U.S ...

Dexcom has pitched the Stelo as a more “health-focused” version of its top-of-the-line CGM, the G7, which made its debut early last year. Though built on the same sensor platform, the Stelo ...